Kronos Bio to be acquired by Concentra for 57c per sare in cash plus CVR
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 01 2025
0mins
Merger Agreement Details: Kronos Bio has agreed to be acquired by Concentra Biosciences for $0.57 per share in cash, along with contingent value rights related to future product candidate dispositions and cost savings.
Shareholder Support and Timeline: The Kronos Bio Board has approved the merger, with significant shareholder support, and the transaction is expected to close by mid-2025, pending certain conditions including a majority tender of shares.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
